Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lin Shen

Showing results (1401-1410 of 1,553) with videos related to

Pageof 156
Sort By:
Cancer Immunology, Immunotherapy : CII|January 5, 2022
Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trialJifang Gong, Junning Cao, Qingyuan Zhang, et al.
Trials|April 16, 2015
Electroacupuncture inhibits chronification of the acute pain of knee osteoarthritis: study protocol for a randomized controlled trialLin-lin Shen, Guo-fu Huang, Wen Tian, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 4, 2023
MiR-455-5p suppresses PDZK1IP1 to promote the motility of oral squamous cell carcinoma and accelerate clinical cancer invasion by regulating partial epithelial-to-mesenchymal transitionSheng-Yen Hsiao, Shang-Mei Weng, Jenn-Ren Hsiao, et al.
Cancer Immunology, Immunotherapy : CII|February 25, 2025
An integrated prognosis prediction model based on real-word clinical characteristics for immunotherapy in advanced esophageal squamous cell carcinomaLiyuan Dong, Yue Ma, Guang Cao, et al.
Hepatology (Baltimore, Md.)|June 14, 2024
Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trialDo-Youn Oh, Masafumi Ikeda, Choong-Kun Lee, et al.
Cancer|December 9, 2025
Chinese expert consensus on diagnosis and treatment of small gastrointestinal stromal tumors (2025 edition)Zhidong Gao, Chao Wang, Jian Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2023
Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 StudiesMichael C Heinrich, Xinhua Zhang, Robin L Jones, et al.
Journal for Immunotherapy of Cancer|June 26, 2023
CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activationJing Gao, Zhengyi Wang, Wenqing Jiang, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|August 30, 2013
[Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport]Lin Shen, Jian-ming Xu, Feng-yi Feng, et al.
Cancer Medicine|June 1, 2023
Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study resultsFortunato Ciardiello, Yung-Jue Bang, Andrés Cervantes, et al.
Pageof 156

Showing results (1401-1410 of 1,553) with videos related to

Sort By:
Pageof 156
Cancer Immunology, Immunotherapy : CII|January 5, 2022
Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trialJifang Gong, Junning Cao, Qingyuan Zhang, et al.
Trials|April 16, 2015
Electroacupuncture inhibits chronification of the acute pain of knee osteoarthritis: study protocol for a randomized controlled trialLin-lin Shen, Guo-fu Huang, Wen Tian, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 4, 2023
MiR-455-5p suppresses PDZK1IP1 to promote the motility of oral squamous cell carcinoma and accelerate clinical cancer invasion by regulating partial epithelial-to-mesenchymal transitionSheng-Yen Hsiao, Shang-Mei Weng, Jenn-Ren Hsiao, et al.
Cancer Immunology, Immunotherapy : CII|February 25, 2025
An integrated prognosis prediction model based on real-word clinical characteristics for immunotherapy in advanced esophageal squamous cell carcinomaLiyuan Dong, Yue Ma, Guang Cao, et al.
Hepatology (Baltimore, Md.)|June 14, 2024
Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trialDo-Youn Oh, Masafumi Ikeda, Choong-Kun Lee, et al.
Cancer|December 9, 2025
Chinese expert consensus on diagnosis and treatment of small gastrointestinal stromal tumors (2025 edition)Zhidong Gao, Chao Wang, Jian Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2023
Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 StudiesMichael C Heinrich, Xinhua Zhang, Robin L Jones, et al.
Journal for Immunotherapy of Cancer|June 26, 2023
CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activationJing Gao, Zhengyi Wang, Wenqing Jiang, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|August 30, 2013
[Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport]Lin Shen, Jian-ming Xu, Feng-yi Feng, et al.
Cancer Medicine|June 1, 2023
Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study resultsFortunato Ciardiello, Yung-Jue Bang, Andrés Cervantes, et al.
Pageof 156